Respiratory failure & ventilation
Dexamethasone for Inpatients With COVID-19 in a National Cohort
Authors' conclusion
In this national multicenter cohort study of inpatients with COVID-19, early administration of dexamethasone was associated with significantly reduced odds of mortality or discharge to hospice in those requiring supplemental oxygen or MV and/or ECMO but not in those requiring no supplemental oxygen or NIPPV.
Study context
- Population
- Adults hospitalised ≥48 hours for COVID-19 respiratory illness, 156 US hospitals, July 2020–October 2021
- Participants
- 80,699 adults · 156 hospitals
- Exposure
- Dexamethasone vs No dexamethasone
- Outcome
- All-cause in-hospital mortality or discharge to hospice
Methodological detailspropensity score-weighted, multicentre
- Propensity score-weighted
- Multicentre
Main finding
As reported in the abstract
In-hospital mortality or discharge to hospice, by oxygen-support subgroup
Dexamethasone vs No dexamethasoneAdjusted odds ratio (95% CI)
Supplemental oxygen
0.92(0.86–0.98)
MV and/or ECMO
0.82(0.68–0.99)
No supplemental oxygen
0.90(0.78–1.03)
NIPPV
0.87(0.73–1.04)
Observational data: associations, not effects.
Further findings
Comorbidity subgroups
- Patients with more comorbidities had greater benefit from dexamethasone
Original publication
Dexamethasone for Inpatients With COVID-19 in a National Cohort. JAMA Netw Open. Published 3 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →